Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Metastatic bladder cancer: Current practice and latest data from ASCO 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.19
Views: 1233

Dr Andrea Necchi, Dr Petros Grivas, Prof Arlene Siefker-Radtke, Prof Rob Jones

Dr Andrea Necchi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) is joined by Dr Petros Grivas (Seattle Cancer Care Alliance, Seattle, USA), Dr Arlene Siefker-Radtke (MD Anderson Cancer Center, Houston, USA) and Professor Rob Jones (Beatson West of Scotland Cancer Centre, Glasgow, UK) to discuss the current clinical landscape and latest data in metastatic bladder cancer at ASCO 2019.

The discussion starts by addressing the experts view on the most exciting challenges faced in their clinical practice for the treatment of patients with advanced bladder cancer. The panel agreed that the emergence of novel therapies and identification of potential biomarkers shows great promise in this patient landscape, however they feel as there is still an unmet need for this patient population.

The conversation then focuses on research into treatment biomarkers in metastatic bladder cancer, with the experts discussing PD-L1 and FGFR as well as tumour mutational burden and the updates from ASCO 2019. Dr Siefker-Radtke and Dr Petros Grivas discuss at what point they test for FGFR when diagnosing a patient with advanced disease and look forward to the impact they feel erdafitinib will have on the patient treatment pathway.

Finally the experts discuss the latest updates presented at ASCO 2019, including the potential of an anti-antiogenic treatment strategies for patients and the role of maintenance immunotherapy in this setting, debating the question as to whether there is difference in benefit to treat patients early with immunotherapy or delay treatment.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).  

Related videos


no rating
Cancer care in Latin America

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation